Embed Size (px)
Trans[us. Sci. Vol. 17, No. 3, pp. III-VI, 1996 Elsevier Science Ltd
Printed in Great Britain
N E W P A T E N T S
Thi s sec t ion con ta ins abs t rac ts of recent ly issued U n i t e d States pa ten t s and pub l i shed pa ten t appl ica t ions flied f rom over 30 coun t r i es unde r the Pa ten t Coopera t ion Trea ty and compi led in accordance w i th in teres t profiles developed by the Editors.
SYNTHETIC, PLASMA-FREE, TRANSFUSIBLE STORAGE
MEDIUM FOR RED BLOOD CELLS AND PLATELETS
Holme Stein; Hcatun William A L Virginia Beach, VA, UNITED STATES assigned to American National Red Cross
enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-I, TNF and leukotrienes) that can cause detrimental side effects, such as fever and inflammation.
PERIPHERAL BLOOD FLOW EVALUATING APPARATUS
The invention is a sterile, plasma-free storage medium for blood components including red blood cells and for platelets processed separately or together. The red cell storage medium includes adenine and a physiologically compatible, aqueous electrolyte solution. In one liter of this electrolyte solution there is between about 3.0 grams and about 25.0 grams of dextrose, between about 3.0 grams and about 6.0 grams of sodium citrate, and between about 2.0 grams and about 4.2 grams of sodium bicarbonate. The red cell storage medium is isotonic and has a pH in a range of between about 6.8 and about 7.4. The red cell storage medium is capable of storing and preserving red cells for at least 49 days.
USE OFNEUTRALSOLUBLE GLUCANPREPARATIONSTO
STIMULATE PLATELET PRODUCTION
Jamas Spiro; Easson D Davidson; Ostroff Gary R Boston, MA, UNITED STATES assigned to Alpha-Beta Technology lnc
The present invention relates to neutral soluble beta-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel beta-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the beta-glucan receptor of human mono-cytes and retains two primary biological (or immunological) activities, (1) the enhancement of microhicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-I and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to
Takatani Setsuo; Sakai Hiroshi Houston, TX, UNITED STATES assigned to Colin Corporation
An apparatus for evaluating a peripheral blood flow of a living subject, including a reflection-type pulse wave detecting device including two pairs of light-emitting and light-receiving elements provided such that a distance between the light-emitting and light-receiving elements of one pair is different from that of the other pair; and a determining device for determining an attenuation coefficient of the light beam emitted by the light-emitting element of each pair, based on (a) an intensity of the light beam which is emitted by the light-emitting element of each pair and (b) an intensity of the light which has been emitted from the light-emitting element of each pair, reflected from skin of the subject, and subsequently received by the light-receiving element of each pair. The apparatus further includes an evaluating device for evaluating peripheral blood flow of the subject, based on a ratio of the attenuation coefficient of the light beam emitted by the light-emitting element of one pair to the attenuation coefficient of the light beam emitted by the light-emitting element of the other pair, and/or, a display which displays a change of the ratio of the attenuation coefficient of the light beam emitted by the light-emitting element of one pair to the attenuation coefficient of the light beam emitted by the light-emitting element of the other pair.
MUTATIONS RENDERING PLATELET GLYCOPROTEIN IB-
ALPHA LESS REACTIVE
Miller Jonathan L; Cunningham Davi; Lyle Vicki A; Finch Clara N Syracuse, NY, UNITED STATES assigned to The Research Foundation of State University of New York
The subject invention provides purified polypeptides encoded by naturally-occurring
VI Transfus. Sci. Vol. 17, No. 3
II~IU~WLVgl ~ ~ A m ' l ~ U l , ~U l l qq~ l ml t
REEDFAX Document Delivery System A service o f Reed Technology and Information Services Inc. 275 Gibraltar Road, Horsham PA 19044, USA
Phone: 1 800-422-1337 Fax: 1 800-421 5585
International Numbers: Phone: 1 215-441-4768
Fax: 1 215-441-5463
R E E D F ~ TM Document Delivery System
We can begin fax transmission of patents within 15 minutes m 24 hours a day m 7 days a week.
We have over 1.9 million patents (1971 forward) and EP and PCT applications on our automated REEDFAX TM Document Delivery System which allows you to use a touchtone phone to order these patents without being limited to business hours
You can now get the patents you need before hours...after hours...over the weekend.. .on hol idays_even when the US PTO is closed because of inclement weather!.
In addition to the patents on our automated system, we are able to deliver all U.S. patents beginning with # 1 to the current week of issue. Patents not on our automated system are delivered from our second location with fax transmission beginning about 1½ hours, Monday-Friday, 8:30am-7:00pm ET. (13.00pm-24.00GMT).
We have no hidden charges at REEDFAX: no sign-on fees, no monthly fees and no minimum charges. You pay only for each patent delivered. Whatever your patent needs are - U.S. or foreign patents, file histories/wrappers, printed or faxed - - we can fulfill them easily and promptly.
P.S. To experience your incredibly fast service, complete and return the FAXForm and we will provide your firm's FIRST FIVE U.S. PATENTS ABSOLUTELY FREE (you pay only for the cost of delivery~)
- @ A member of the Reed Elsevier pie group